This listing of claims will replace all prior versions, and listings, of claims in the application (note that amendments are highlighted in **bold**):

Listing of Claims:

1. (Currently Amended) A compound represented by the structural formula



formula I

or a pharmaceutically acceptable salt or solvate wherein

X is $-CH_2-$, $-SO_2-$, carbonyl, $-CHCH_3$ or $-C(CH_3)_2-$;

Y is $-(CR^2R^3)_pC(O)NH-$, wherein p is a number from 1 to 3 and when p is more than 1, each (CR^2R^3) can be the same or different;

n is 0, such that no connecting bond exists between the two carbons adjacent to the nitrogen;

r is 1;

Ar is aryl or R^6-substituted aryl;

R^1 is hydrogen, ~~-alkyl, -cycloalkyl, aralkyl, heterocyclyl, heteroaralkyl, $-C(O)R^5$, $-C(O)OR^5$, $-C(O)NR^8R^9$, $-SO_2R^5$, $-SO_2NR^8R^9$, aryl, heteroaryl, $-CF_3$, -alkyl substituted with R^{10}, -cycloalkylalkyl, -cycloalkylalkyl substituted with R^{10} on the cycloalkyl ring,~~

methyl, ethyl, hydroxyethyl, cyclobutyl, cyclopentyl, cycloheptyl, -propyl, $-SO_2CH_3$, $-SO_2N(CH_3)_2$, $-COCH_3$, $-C(O)OC(CH_3)_3$, isopropyl, cyclopropylmethyl,




or

;

R^2 and R^3 can be the same or different, each being independently hydrogen or –alkyl; or R^2 and R^3 can be joined together with the carbon to which they are attached to form a 3 to 7-membered ring;

R^4 is aryl, R^7-substituted aryl, or

Y-R^4 is 
;

R^5 is -alkyl, aryl, aralkyl or heteroaryl;

R^6 is 1 to 3 substituents, each R^6 can be the same or different and each is independently selected from the group consisting of -OH, -alkoxy, $-OCF_3$, -CN, -alkyl, halogen, $-NR^8R^9$, $-C(O)NR^8R^9$, $-NR^8SO_2R^5$, $-SO_2NR^8R^9$, $-SO_2R^5$, $-C(O)R^5$, $-C(O)OR^5$, $-CF_3$, $-(CR^2R^3)_{p''}NR^8R^9$ where p'' is a number from 1 to 3, -CHO, $-C{=}NOR^8$, $-NR^8C(O)R^5$, $-C(=NH)NR^8R^9$, $-C(=NCN)NR^8R^9$, 
,

,

and

;

R^7 is hydrogen or 1 to 4 substituents, each R^7 can be the same or different and each is independently selected from the group consisting of -OH, -alkoxy, $-OCF_3$, -CN, halogen, -nitro, $-NR^8R^9$, $-NR^8C(O)R^5$, $-C(O)NR^8R^9$, $-NR^8SO_2R^5$, $-SO_2NR^8R^9$, $-SO_2R^5$, $-C(O)R^5$, $-C(O)OR^8$, $-CF_3$, $-(CR^2R^3)_{p''}NR^8R^9$, $-(CR^2R^3)_{p''}NR^8C(O)R^5$ where p'' is a number from 1 to 3, $-C(=NH)NR^8R^9$, $-C(=NCN)NR^8R^9$ and -CHO; or two adjacent R^7 groups can be joined together to form a methylenedioxy or ethylenedioxy group;

R^8 is hydrogen or –alkyl;

R^9 is hydrogen, -alkyl, aryl, substituted aryl, heteroaryl or aralkyl; and

R^{10} is –OH, -alkoxy, -cycloalkyl, -cycloalkylalkyl, -C(O)NR^8R^9, -NR^8R^9, -$NR^8SO_2R^5$, -$NR^8C(O)R^5$, -$NR^8C(O)OR^5$, -$NR^8C(O)NR^8R^9$,-C(O)OH or –$C(O)OR^5$.

2. (previously presented) The compound of claim 1 wherein
X is -SO_2-;
R^2 and R^3 are hydrogen or alkyl;
and
n is 0.

3. (original) The compound of claim 2 wherein R^2 and R^3 are hydrogen.

4. (previously presented) The compound of claim 1 wherein
X is carbonyl;

R^2 and R^3 are hydrogen or alkyl;
and
n is 0.

5. (original) The compound of claim 4 wherein R^2 and R^3 are hydrogen.

6. (previously presented) The compound of claim 1 wherein
X is -CH_2-;
R^1 is hydrogen, -alkyl, -cycloalkyl, -cycloalkylalkyl, heteroaralkyl, heterocyclyl, -alkyl substituted with -cycloalkyl, -alkyl substituted with R^{10}, -$SO_2NR^8R^9$, -SO_2R^5; -C(O)R^5 or –$C(O)OR^5$;
R^2 and R^3 are hydrogen or alkyl;
n is 0;
and
Ar is aryl or R^6-substituted aryl.

7. (original) The compound of claim 6 wherein

R^1 is hydrogen, methyl, ethyl, hydroxyethyl, cyclobutyl, cyclopentyl, cycloheptyl, -propyl, $-SO_2CH_3$, $-SO_2N(CH_3)_2$, $-COCH_3$, $-C(O)OC(CH_3)_3$, isopropyl, cyclopropylmethyl, heteroaryl,  ,  , or  ;

R^2 and R^3 are hydrogen;

Ar is R^6-substituted aryl;

R^6 is 1 to 5 substituents which can be the same or different and each is independently selected from the group consisting of halogen, $-CF_3$, $-OCF_3$, -CN, -CHO, $-SO_2R^5$, $-C(O)OR^8$, $-C(O)R^5$, $-C(O)NR^8R^9$ and  ;

and

R^7 is two substituents which can be the same or different and independently selected from halogen, -CN and $-CF_3$.

8. (original) The compound of claim 7 wherein R^6 is one substituent.

9. (original) The compound of claim 8 wherein R^6 is at the meta position of Ar.

10. (original) The compound of claim 9 wherein R^6 is –CN.

11. (original) The compound of claim 9 wherein R^6 is -C(=NH)NHaryl or $-C(=NH)NH_2$.

12. (original) The compound of claim 10 wherein R^7 is selected from the group consisting of Cl, F and $-CF_3$.

13. (Currently amended) The compound of claim ~~1~~ **12** wherein R^1 is hydrogen, methyl, ethyl, hydroxyethyl, cyclobutyl, cyclopentyl, cycloheptyl, -propyl, $-SO_2CH_3$, $-SO_2N(CH_3)_2$,

$-COCH_3$, $-C(O)OC(CH_3)_3$, isopropyl, cyclopropylmethyl, ~~heteroaryl~~,



14. (previously presented) The compound of claim 1 wherein

X is $-CH_2-$;

$Y-R^4$ is  ;

n is 0;

Ar is R^6-substituted aryl;

R^1 is alkyl or cyclopropylmethyl;

R^6 is –CN and is substituted at the meta position of Ar.

and

R^7 is hydrogen or halogen.

15. (original) The compound of claim 14 wherein R^7 is chloride or fluoride.

16. (original) A compound selected from the group consisting of

8b	
8c	

8d	
8e	
8f	
7d	
7b	
7c	

7a	
7e	
8a	
10c	
11c	

11d	
11e	
11f	
11g	
8g	

8h	
8i	
11h	
11i	
11b	
11j	

11a	
12a	
12d	
12e	
12f	
30a	

30b	
30c	
and 30d	

or a pharmaceutically acceptable salt or solvate.

17. (original) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in combination with at least one pharmaceutically acceptable carrier.

18. (previously presented) A method of treating obesity, hyperphagia or diabetes comprising administering a therapeutically effective amount of at least one compound of claim 1 to a patient in need of such treatment.

19. (previously presented) A method of treating hyperphagia comprising administering to a patient in need of such treatment a therapeutically effective

amount of at least one compound of claim 1, or a pharmaceutically acceptable salt or solvate of said compound.

20. (original) A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 16 in combination with at least one pharmaceutically acceptable carrier.

21. (previously presented) A method of treating obesity, hyperphagia or diabetes comprising administering a therapeutically effective amount of at least one compound of claim 16 to a patient in need of such treatment.

22. (previously presented) A method of treating hyperphagia comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one compound of claim 16, or a pharmaceutically acceptable salt or solvate of said compound.

Claims 23-30 (canceled)